Dietary Therapies: Emerging Paradigms in Therapy of Drug Resistant Epilepsy in Children : Based on 6th Dr. I. C. Verma Excellence in Research Award Oration.
Level 5 - mechanism / opinion, no new human data
Narrative review and award oration without systematic search or pooled quantitative analysis.
PubMed 30242606 · doi:10.1007/s12098-018-2779-9
What was done
This paper is a narrative review (based on the 6th Dr. I. C. Verma Excellence in Research Award Oration) evaluating dietary therapies for children with pharmacoresistant epilepsy. It discusses the mechanisms, historical context, and clinical variants of dietary management, including the classic Ketogenic Diet (KD), Modified Atkins Diet (MAD), Low Glycemic Index Treatment (LGIT), and Medium Chain Triglyceride Ketogenic Diet (MCT KD).
What was found
The abstract provides no primary data, patient numbers, or quantitative efficacy metrics. It notes qualitatively that dietary regimens reduce epileptogenesis—most likely via ketone body production—and that less restrictive variants (MAD, LGIT, and MCT KD) demonstrate comparable efficacy to the classic ketogenic diet with improved palatability and fewer side effects.
Why it matters
Highlights non-surgical, non-pharmacological dietary interventions for the approximately one-third of pediatric epilepsy patients who are drug-resistant and cannot access or undergo surgical resections or vagal nerve stimulation.
Limits
The abstract contains no quantitative data, randomized comparison statistics, or systematic review methodology. Specific tolerability rates, retention rates, adverse events, and precise comparative seizure reduction rates are not reported.
Cited by
- supports Ketogenic metabolic therapy has been used to manage pediatric epilepsy for decades.